Aortic Valve Disorder Clinical Trial
Official title:
CO2 Insufflation vs Lund De-airing Technique For Open Left Heart Surgery - Safety and Efficacy
Verified date | October 2013 |
Source | Lund University |
Contact | n/a |
Is FDA regulated | No |
Health authority | Sweden: The National Board of Health and Welfare |
Study type | Interventional |
To evaluate which of the two de-airing methods (CO2 insufflation vs. Lund de-airing
technique) can shorten the left heart de-airing time and prevent or minimize cerebral air
emboli during open surgery involving exposure of the left heart to the ambient air.
To evaluate the cost effectiveness and possible side effects of CO2 de-airing technique
compared to Lund de-airing technique.
Status | Completed |
Enrollment | 20 |
Est. completion date | October 2009 |
Est. primary completion date | October 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 90 Years |
Eligibility |
Inclusion Criteria: - Patients planned for aortic valve/root replacement or repair will be selected for the study Exclusion Criteria: Patients with known - chronic obstructive pulmonary disease, - emphysema, - previous thoracic or cardiac surgery, - history of CVA or stroke and - evidence of intraoperative pleural adhesions will be excluded from the study. - Patients requiring internal mammary artery coronary bypass will also be excluded. |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Lund University |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Air Microemboli Registered Over the Middle Cerebral Arteries by On-line Trans-cranial Echo-Doppler (TCD). | The number of air microemboli (also referred to as gaseous microembolic signals) was concomitantly counted in the right and left medial cerebral artery. The number of signals from the right and the left medial cerebral artery were summed, and presented as the total sum of the gaseous micromebolic signals from the right and left side. Counting of gaseous microembolic signals was done during three time intervals: Before cardiac ejection, after cardiac ejection and during 10 minutes after cardiopulmonary bypass. | Before cardiac ejection | Yes |
Primary | Number of Air Microemboli Registered Over the Middle Cerebral Arteries by On-line Trans-cranial Echo-Doppler (TCD). | The number of air microemboli (also referred to as gaseous microembolic signals) was concomitantly counted in the right and left medial cerebral artery. The number of signals from the right and the left medial cerebral artery were summed, and presented as the total sum of the gaseous micromebolic signals from the right and left side. Counting of gaseous microembolic signals was done during three time intervals: Before cardiac ejection, after cardiac ejection and during 10 minutes after cardiopulmonary bypass. | After cardiac ejection | Yes |
Primary | Number of Air Microemboli Registered Over the Middle Cerebral Arteries by On-line Trans-cranial Echo-Doppler (TCD). | The number of air microemboli (also referred to as gaseous microembolic signals) was concomitantly counted in the right and left medial cerebral artery. The number of signals from the right and the left medial cerebral artery were summed, and presented as the total sum of the gaseous micromebolic signals from the right and left side. Counting of gaseous microembolic signals was done during three time intervals: Before cardiac ejection, after cardiac ejection and during 10 minutes after cardiopulmonary bypass. | During 10 minutes after cardiopulmonary bypass | Yes |
Primary | Number of Participants With <=Grade I Gas Emboli as Assessed by Trans-esophageal Echocardiography TEE). | Grade 0, no residual gas emboli; grade I, gas emboli observed in 1 of the 3 anatomic areas - left atrium, left ventricle or aortic root during 1 cardiac cycle; grade II, gas emboli observed simultaneously in 2 of the 3 anatomic areas during 1 cardiac cycle; grade III, gas emboli observed simultaneously in all 3 anatomic areas during 1 cardiac cycle. | 0-3 minutes after end of cardiopulmonary bypass | Yes |
Primary | Number of Participants With <=Grade I Gas Emboli as Assessed by Trans-esophageal Echocardiography TEE). | Grade 0, no residual gas emboli; grade I, gas emboli observed in 1 of the 3 anatomic areas - left atrium, left ventricle or aortic root during 1 cardiac cycle; grade II, gas emboli observed simultaneously in 2 of the 3 anatomic areas during 1 cardiac cycle; grade III, gas emboli observed simultaneously in all 3 anatomic areas during 1 cardiac cycle. | 3-6 minutes after end of cardiopulmonary bypass | Yes |
Primary | Number of Participants With <=Grade I Gas Emboli as Assessed by Trans-esophageal Echocardiography TEE). | Grade 0, no residual gas emboli; grade I, gas emboli observed in 1 of the 3 anatomic areas - left atrium, left ventricle or aortic root during 1 cardiac cycle; grade II, gas emboli observed simultaneously in 2 of the 3 anatomic areas during 1 cardiac cycle; grade III, gas emboli observed simultaneously in all 3 anatomic areas during 1 cardiac cycle. | 6-10 minutes after end of cardiopulmonary bypass | Yes |
Secondary | Total Time Required for De-airing | The total de-airing time as measured in minutes. | After removal of aortic cross-clamp to complete de-airing, an average of 11 minutes | No |
Secondary | De-airing Time Before Cardiac Ejection | Time in minutes starting at t1 (removal of aortic cross clamp) and ending at t2 (beginning of cardiac ejection). | Measured during intraoperative course | No |
Secondary | De-airing Time After Cardiac Ejection | The duration in minutes of the period after cardiac ejection to finished de-airing procedure. | During de-airing procedure | No |
Secondary | Oxygenator Gas Flow at 45 Minutes of CPB | The amount of carbon dioxide gas flow through the oxygenator was measured and compared between groups. | Intraoperative | No |
Secondary | pH at 45 Min of CPB | pH measured by arterial bloodgas at 45 minutes of CPB, comparison between groups | Intraoperative | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02910349 -
Novel Cardiac Imaging Prognostic Markers of Clinical Outcome in Patients With Chronic Aortic Regurgitation
|
||
Completed |
NCT03298932 -
2D Strain of Right Ventricle in Peroperative of Cardiac Surgery
|
||
Completed |
NCT01171625 -
Carpentier-Edwards PERIMOUNT Magna Ease Pericardial Bioprosthesis, Model 3300TFX
|
N/A | |
Completed |
NCT01959503 -
Progel Vascular Sealant
|
N/A | |
Completed |
NCT01353287 -
Transcatheter Aortic Valve Intervention-Live Transmission
|
N/A | |
Completed |
NCT03016169 -
Trifectaâ„¢ GT Post Market Clinical Follow-up
|
N/A | |
Terminated |
NCT02678871 -
Combined Transcatheter Aortic Valve Implantation and Percutaneous Closure of the Left Atrial Appendage
|
N/A | |
Suspended |
NCT01536717 -
Comparison of the Local Anaesthetics Articaine and Bupivacaine in Treatment of Acute Sternum Pain After Heart Surgery
|
Phase 4 | |
Completed |
NCT01651052 -
Clinical Trial of the Edwards Aortic Bioprosthesis, Model 11000
|
N/A | |
Terminated |
NCT02696226 -
Frequency of Reduced Leaflet Motion After Surgical Aortic Valve Replacement and Transcatheter Aortic Valve Replacement.
|
N/A | |
Completed |
NCT01619982 -
Pre-operative Prophylaxis With Vancomycin and Cefazolin in Pediatric Cardiovascular Surgery Patients
|
Phase 4 |